Acquisition - February 16, 2016
Dilaforette signs agreement with Arabian Gulf University
Dilaforette, focused on treatments for patients with sickle-cell disease, and Arabian Gulf University, based in Bahrain, have signed a Clinical Collaboration agreement for the Phase 2 proof of concept trial of sevuparin in patients with Sickle Cell Disease (SCD) experiencing acute Vaso-Occlusive Crisis (VOC). Under the scope of the agreement, Dilaforette and AGU’s collaboration will […]
